Albert Einstein College of Medicine enters agreement with Jiangsu Hengrui Medicine

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

ALBERT EINSTEIN COLLEGE OF MEDICINE entered into a research agreement with Jiangsu Hengrui Medicine Co. Ltd. to develop innovative cancer therapies. The collaboration is the first between Einstein and a pharmaceutical company based in China.

Jiangsu Hengrui Medicine, established in 1970, is a fully integrated pharmaceutical company with annual net sales of over $1.2 billion. Hengrui’s products and research span therapeutic areas including oncology and hematology, anesthesiology and pain management, cardiovascular and metabolic diseases, contrast media and inflammation.

Table of Contents

YOU MAY BE INTERESTED IN

In his first sit-down interview since beginning his role as FDA commissioner 17 days earlier, Marty Makary, a former Johns Hopkins surgeon and the only Trump pick for HHS whose confirmation received Democratic support, said he would speed up approvals for rare-disease treatments by reducing reliance on animal testing and shifting towards organoids and computational models. 
The American Cancer Society’s recent report on the increasing incidence rates of colorectal cancer in young adults once again rang an alarm bell for adults over 45 to get checked, especially if they are having symptoms. But as an oncologist with more than 40 years of experience, I also believe that this should be a clarion call to scientists and researchers, and for regulators at the FDA.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login